Capricor Therapeutics Announces for the Treatment of Duchenne Muscular Dystrophy
Capricor Therapeutics, Inc. (CAPR)
Last capricor therapeutics, inc. earnings: 3/18 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
capricor.com/investors
Company Research
Source: GlobeNewswire
SAN DIEGO, June 25, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has scheduled a Pre-BLA (Biologics License Application) meeting with the Company in the third quarter of 2024 for deramiocel (CAP-1002), for the treatment of Duchenne Muscular Dystrophy (DMD). Capricor’s goal for this meeting will be to finalize its BLA filing plans based on all currently available data as well as to work with the FDA to outline the rolling BLA submission timeline. “We continue to move rapidly towards potential approval of deramiocel for the treatment of DMD,” said Linda Marbán, Ph.D., Capricor’s chief executive officer. “We now have formally scheduled our Pre-BLA meeting with the FDA, which will finalize our BLA filing plans and discuss available options to expedite the filing of our BLA. We recogni
Show less
Read more
Impact Snapshot
Event Time:
CAPR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CAPR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CAPR alerts
High impacting Capricor Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CAPR
News
- Exosome Therapies on the Rise as 70+ Major Companies Driving Development in the Field | DelveInsight [Yahoo! Finance]Yahoo! Finance
- Here's What Could Help Capricor (CAPR) Maintain Its Recent Price Strength [Yahoo! Finance]Yahoo! Finance
- Capricor Therapeutics files to sell 2.8M shares of common stock for holders [Seeking Alpha]Seeking Alpha
- Capricor Therapeutics Inc (NASDAQ: CAPR) is now covered by analysts at Piper Sandler. They set an "overweight" rating and a $35.00 price target on the stock.MarketBeat
- Capricor Therapeutics Announces Closing of Underwritten Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional SharesGlobeNewswire
CAPR
Earnings
- 8/7/24 - Miss
CAPR
Sec Filings
- 10/24/24 - Form SC
- 10/22/24 - Form S-3
- 10/17/24 - Form 424B5
- CAPR's page on the SEC website